Dissecting the Metabolic Rewiring Mediated by SMARCB1 Loss in Metastatic Bladder Cancer
About This Grant
Project Summary Bladder cancer (BLCA), the sixth most common cancer in the United States and 9th overall among all cancers, is rarely diagnosed in individuals aged <40 years. The Cancer Genome Atlas (TCGA) described the genomic landscape of BLCA patients and noted that >60% of cases have alterations in subunits of SWItch/sucrose non- fermentable (SWI/SNF) nucleosome remodeling complexes, such as SMARCB1, also known as integrase interactor 1 (INI-1). Presently, the response rate of BLCA to standard-of-care therapies is relatively low, and therefore, the identification of novel metabolic pathway-mediated druggable targets is urgently needed. Our preliminary data demonstrate that SMARCB1 loss expression has a significantly worse prognosis in patients with BLCA. Orthotopically implanted SMARCB1-knockout (KO) xenograft shows enhanced tumor growth and metastasis. While attempting to identify the metabolic landscape mediated by SMARCB1 loss BLCA, we have identified altered methionine metabolism, nucleotide synthesis, and glutathione metabolism. Our current proposal will seek to define further the metabolic pathway by SMARCB1 loss in BLCA progression as well as immunometabolism and determine whether the key pathways can be therapeutically targeted for the treatment of BLCA. In aim 1, Determine the metabolic alteration by SMARCB1-loss BLCA tumor cells and tumor infiltrating immune cells. In aim 2, Trace the key metabolic pathways in SMARCB1 loss metastatic BLCA. At the level of basic biology, this project aims to understand the metabolic rewiring mediated by SMARCB1 loss in BLCA progression as well as immunometabolism and metastasis by utilizing cutting-edge high-resolution mass spectrometry techniques to profile the metastatic mediated tumors cells and immunometabolism harboring SMARCB1 loss. This will further examine the pathway-specific metabolic regulation non-invasive liquid diet delivery of stable isotopes into mouse models, which will lay the foundation to test the therapeutic strategy in the future.
Grant Summary
Dissecting the Metabolic Rewiring Mediated by SMARCB1 Loss in Metastatic Bladder Cancer is a NCI - National Cancer Institute grant providing up to $160K for university, nonprofit, healthcare org. Applications are due 2028-04-30 (open). Check eligibility and apply with FindGrants.
Not quite the right fit?
Search 9,000+ open grants, or get matches ranked for your organization — free.
Focus Areas
Eligibility
How to Apply
Up to $160K
2028-04-30
- 1Confirm your organization is eligible for Dissecting the Metabolic Rewiring Mediated by SMARCB1 Loss in Metastatic Bladder Cancer from NCI - National Cancer Institute, checking organization type, location, and any population or project requirements.
- 2Gather the required documents and information, including your organization details, project plan, and budget figures.
- 3Draft your application narrative and budget addressing the funder's priorities and review criteria. FindGrants can draft each section for you to review and edit.
- 4Review every section against the requirements checklist, then export a submission-ready application pack and submit it to NCI - National Cancer Institute before the deadline.
Don't want to draft it yourself?
We'll draft the complete application against NCI - National Cancer Institute's requirements, run a quality review, and email you a submission-ready PDF plus an editable Word doc within 5 business days. Most orders deliver in 24-48 hours. Flat $399, any grant size.
AI Requirement Analysis
Detailed requirements not yet analyzed
Have the NOFO? Paste it below for AI-powered requirement analysis.
Dissecting the Metabolic Rewiring Mediated by SMARCB1 Loss in Metastatic Bladder Cancer: Frequently Asked Questions
Who is eligible for the Dissecting the Metabolic Rewiring Mediated by SMARCB1 Loss in Metastatic Bladder Cancer?
Dissecting the Metabolic Rewiring Mediated by SMARCB1 Loss in Metastatic Bladder Cancer is offered by NCI - National Cancer Institute and is generally open to university, nonprofit, healthcare org. It is open to organizations nationwide unless the funder specifies otherwise. Review the specific eligibility terms before applying, since funders set their own requirements around organization type, location, and the population or project being served.
How much funding does the Dissecting the Metabolic Rewiring Mediated by SMARCB1 Loss in Metastatic Bladder Cancer provide?
Dissecting the Metabolic Rewiring Mediated by SMARCB1 Loss in Metastatic Bladder Cancer provides up to $160K per award from NCI - National Cancer Institute. Actual award sizes depend on the scope of your project, available program funds, and the number of applicants, so build a budget that reflects realistic, allowable costs rather than the maximum figure.
When is the Dissecting the Metabolic Rewiring Mediated by SMARCB1 Loss in Metastatic Bladder Cancer deadline?
Applications for Dissecting the Metabolic Rewiring Mediated by SMARCB1 Loss in Metastatic Bladder Cancer are due 2028-04-30 (open). Because deadlines can change, verify the date with the funder, NCI - National Cancer Institute, and give yourself enough time to prepare a complete, competitive application before the close date.
How do you apply for the Dissecting the Metabolic Rewiring Mediated by SMARCB1 Loss in Metastatic Bladder Cancer?
To apply for Dissecting the Metabolic Rewiring Mediated by SMARCB1 Loss in Metastatic Bladder Cancer, confirm your eligibility, gather the required documents, and prepare a narrative and budget that address the funder's priorities. FindGrants guides you step by step and can draft each section, then exports a submission-ready application pack for this grant from NCI - National Cancer Institute.